| Hey there, savvy investors! Ready for something different? This week, I'm digging into two stocks that are flying under the radar – one in the energy sector that's about to flip the script, and another biotech play that could deliver a massive earnings surprise. Let's get into it. ProPetro (PUMP): The Fracking Company Going ElectricI know what you're thinking: "Another fracking company? In 2025?" But hear me out – this isn't your typical pressure pumping story. Here's the plot twist: While everyone else in the frac business is struggling (and I mean really struggling), ProPetro is building something completely different – a power generation business that could change everything. The PROPWR segment – launched late last year – is about to start printing money. They've got 220 MW of power capacity on order, with deliveries starting this quarter. And get this: they just locked in a 10-year contract for 80 MW with a Permian operator. That's not a rental – that's a long-term, take-or-pay deal with guaranteed cash flow. Why does this matter? While their core frac business is down (Q3 guidance shows 11-12 spreads vs. 14-15 in Q1), the power segment is expected to add $45-60 million in EBITDA for 2026. That's just from the equipment coming online early next year! The kicker: PUMP is the only frac company expected to deliver positive EBITDA growth in 2026. Read that again. Every other player in this space is shrinking, but ProPetro is growing. And the balance sheet? Cleanest in the entire peer group. Net debt plus lease liabilities is basically zero – less than 0.1x EBITDA. While competitors are drowning in debt, PUMP has flexibility and firepower. The cherry on top: It's the cheapest stock in its group. Despite having the strongest balance sheet and being the only one with growth, it's trading at a discount. Plus, there's 15% short interest that's going to need covering once this power story gets more attention. Corcept Therapeutics (CORT): The Earnings Surprise Nobody Sees ComingNow for the biotech play that could blow past expectations in a major way. My bold prediction: Corcept is going to report Q3 earnings of $0.29 per share. Analysts? They're expecting $0.17. That's a potential 70% beat – and here's why I'm confident. The backstory: Corcept's been missing revenue estimates for three straight quarters because their single pharmacy got overwhelmed with prescriptions. But last quarter, they posted their biggest revenue ever at $194 million, up $37 million from Q1. The math that's got me excited: - Analyst consensus expects $224 million in revenue (I'm at $225 million)
- But my EPS estimate is way higher – here's why
Research & Development costs have been flat for over a year, and I'm only building in modest increases. Meanwhile, analysts seem to be overestimating expenses. With 98% gross margins, every dollar matters, and the math points to a significant earnings beat. But wait, there's a bigger story here: Corcept's patient opportunity just exploded from 10,000 to over 1 MILLION. Their CATALYST study data for hard-to-treat diabetes is generating insane interest. One medical conference had 500 people show up for a room with 225 seats – people were standing everywhere. The game-changer: Their new drug Relacorilant (FDA decision by December 30th) could eliminate the generic threat from Teva entirely. If approved, it essentially renders the Teva legal battles moot because it's more effective than their current drug Korlym. Long-term vision: Management is guiding for $3-5 billion in endocrinology revenue alone by 2028-2030. From their current run rate, that's 26% to 77% annual growth. And that's before counting their oncology pipeline. The Week Ahead: What to WatchFor ProPetro: Watch for Q3 results and any updates on additional power contracts. If they announce more long-term deals, expect that short interest to start covering fast. For Corcept: Q3 earnings could be the catalyst that breaks the stock out of its $65-$80 range (it just hit the $80s). A beat on my scale would be massive for sentiment. The Smart Money MoveHere's what makes these two so compelling: they're both contrarian plays with clear catalysts. ProPetro is zigging while everyone else zags – building a power business while competitors cut costs. Corcept is setting up for an earnings surprise while expanding into a million-patient market. My take? Both stocks have asymmetric risk/reward. ProPetro offers growth in a beaten-down sector with the best balance sheet. Corcept offers a near-term catalyst (earnings beat) plus long-term explosive growth potential. The beauty? You don't need to pick one. These serve completely different roles in a portfolio – one's energy infrastructure with contracted cash flows, the other's biotech innovation with massive upside. Which one speaks to you? The power play or the pharma surprise? Let me know what you're thinking! Giving away free access to our scanner this weekend! If you want in on the action, this is your window. Experience automated level detection across all markets. FREE weekend access expires Monday morning. Grab Your Window Weekend action. FREE access. Limited time. Stay sharp, Your Market Scout FindBetterTrades | 
Post a Comment
Post a Comment